Gsk Share Discussion Threads

[essentialinvestor] 12/11/2017 13:38

Thanks Tim, appreciated.

[tim 3] 12/11/2017 13:31

EIYes chart wise could easily see it dropping below 1300 to support hope I am wrong though charting is all about probability after all but even if it does drop that low or below will still hold as to me this is cheap at current levels let alone lower.

[wormhasturned] 12/11/2017 12:21

If the market tanks, cos. like pharma and food retailers always attract the money, this is still a global giant in the pharma world, just going through a rough patch!

[wormhasturned] 12/11/2017 12:20

Forget broker recs., it is their interest to drive the price up or down, they would still advise clients to buy, top-slice or sell to create business, this is a buy at this level purely on the basis of its recent performance. There are clouds, dividend, Advair patent, the Novartis Put, debt, Govt. Healthcare reform but cash flow is strong, costs are being cut and capital invested where necessary. This is almost at a two year low, has fallen significantly recently on poor communication by the CEO., if there doubt about her strategy and ability she would be under pressure to resign, it would hurt the stock initially, but will bounce back, all that value from the Glaxo/SmithKline merger has been eradicated, this will receive a takeover if it does not recover soon, it’s been in the frame not so long ago in the rumour mill, the SG. target is like pharmageddon for this stock, may be reached, but the valuation would become ridiculous if it did, and EW. would definitely be on the block, and her career in tatters!

[ny boy] 12/11/2017 11:36

So much for broker recs, useless, all over the friggin place lol

Stick a pin in

Will buy more down to 12’s

[essentialinvestor] 12/11/2017 10:46

Tim, 1280-1290 ?.

[philanderer] 12/11/2017 09:34

updated:

9th nov Soc Gen sell tp 1075p
8th nov Beaufort buy tp 1450p
7th nov Morgan Stanley underweight tp 1450p
6th nov Investec hold -
2nd nov Berenberg buy tp 1760p
1st nov Kepler reduce tp 1340p
31st oct Jefferies buy tp 1540p
27th oct Credit Suisse neutral tp 1600p
27th oct Barclays equal weight tp 1450p
27th oct Goldmans buy tp 1775p
27th oct JP Morgan Caz neutral tp 1330p
27th oct Deutsche hold tp 1500p
26th oct BOA Merril Lynch neutral tp 1550p
26th oct HSBC buy tp 1925p
26th oct S&P Global hold tp 1510p
26th oct Liberum buy tp 1760p
26th oct Oddo BHF neutral -

25th oct ++++ Q3 results ++++

[cyberian] 11/11/2017 17:03

vGlaxoSmithKline Plc : GSK-US: Dividend Analysis : November 10th, 2017 (record date) : By the numbers : November 10, 2017
November 10, 2017 by CapitalCube
Get free summary analysis
Our analysis is based on comparing GlaxoSmithKline Plc with the following peers – Astrazeneca PLC Sponsored ADR, Merck & Co., Inc., Pfizer Inc., Novartis AG Sponsored ADR, Sanofi Sponsored ADR, Teva Pharmaceutical Industries Limited Sponsored ADR, Shire PLC Sponsored ADR, Dynavax Technologies Corporation and Innoviva, Inc. (AZN-US, MRK-US, PFE-US, NVS-US, SNY-US, TEVA-US, SHPG-US, DVAX-US and INVA-US).

GlaxoSmithKline Plc’s dividend yield is 5.72 percent and its dividend payout is 169.76 percent. This compares to a peer median dividend yield of 3.49 percent and a payout level of 83.28 percent. This type of dividend performance might make it a good stock for dividend investors. In addition, the company’s relatively good dividend quality score of 67 out of a possible score of 100 points to some sustainability of its robust payout ratio, and underscores its attractiveness for dividend investors seeking current income.

Dividend Yield
Dividend Quality Score
Dividend Quality Overview

Over the last twelve months (prior to September 30, 2017), GSK-US paid a high quality dividend, which represents a yield of 5.72% at the current price.
Dividend quality trend has not been consistent over the last five years. Dividends were paid during each of these years — of these 2 were high quality, 1 was medium quality and 2 were low quality.
The ending cash balance, with a dividend coverage of 1.36x, provides a moderate cushion in case of a significant reduction of cash flows in the future.
Dividend Quality Score Vs Dividend Yield
Quadrant label definitions. Hover to know more

High Score;High Yield, High Score;Low Yield, Low Score;Low Yield, Low Score;High Yield
Dividend Coverage

Over the last twelve months (prior to September 30, 2017), GSK-US paid a high quality dividend.

The source of the company’s cash to support the dividend paid over the last twelve months is operating cash flow (coverage of 1.67x), investing cash flow (coverage of -0.34x), issuance cash flow (coverage of 0.06x) and twelve-month prior cash (coverage of 1.28x), for a total dividend coverage of 2.36x.

GSK-US’s issuance cash flow includes outflows from net debt repayment (coverage of -0.29x) and net share buybacks (coverage of -0.00x). Thus, the total coverage including share buybacks is 2.36x, which reflects our assumption that the cash paid for share buybacks is discretionary and could instead be used to pay dividends.

Dividend Coverage by Cash Flow (TTM)
These coverage ratio factors imply that the firm’s dividends are wholly paid from operating and investing cash flows net of any debt repayments, which suggests a high dividend quality.

Dividend History

Item 2012-12-31 2013-12-31 2014-12-31 2015-12-31 2016-12-31 Latest
Dividend Yield (%) 5.7 4.51 6.09 6.05 6.96 5.72
Dividend Payout (%) 81.63 71.34 139.07 44.67 395.52 169.76
A complete list of metrics and analysis is available on the company page.



Company Profile


GlaxoSmithKline Plc’s dividend yield is 5.72 percent and its dividend payout is 169.76 percent. This compares to a peer median dividend yield of 3.49 percent and a payout level of 83.28 percent. This type of dividend performance might make it a good stock for dividend investors. In addition, the company’s relatively good dividend quality score of 67 out of a possible score of 100 points to some sustainability of its robust payout ratio, and underscores its attractiveness for dividend investors seeking current income.

Dividend Yield
Dividend Quality Score
Dividend Quality Overview

[cyberian] 11/11/2017 14:39

Can't see a review or price target on Hargreaves Lansdown comprehensive list from SocGen for at least 6 months..so not that bothered. If you go to Yahoo Finance for the ADR share price for GSK you will see various articles/comments listed..the most recent was on by Capital Cube (last night) on GSK Dividend analysis...sorry can't cut and paste but appears quite relevant, well presented, and well constructed, with a rather favourable outlook. I do think that our CEO's comments at the conference call were "taken out of context" (a favourable headline these days!! Since then you can see that she has taken concrete steps to shake up the drug and R&D side of things, and will I believe address recent short comings in marketing drug portfolio in China. The latter can be remedied with right personnel, and like to see this key market better addressed. Also we have had the very favourable new appointment (he starts in January 1st 2018), and they have had some favourable clearances on some key drugs by the US Drug regulators. The divi prospects/concerns for 2019 and beyond are just market gossip with some having and agenda to lower the share price and to make a turn...pretty sure that we will see a reversal soon, but have to be patient while some play the share price a little longer.

[mj19] 11/11/2017 13:02

GlaxoSmithKline plc 30.4% Potential Upside Indicated by Liberum CapitalPosted by: Amilia Stone 9th November 2017GlaxoSmithKline plc with EPIC/TICKER (LON:GSK) has had its stock rating noted as 'Reiterates' with the recommendation being set at 'BUY' this morning by analysts at Liberum Capital. GlaxoSmithKline plc are listed in the Health Care sector within UK Main Market. Liberum Capital have set their target price at 1760 GBX on its stock

[mj19] 11/11/2017 13:00

SummaryDuring the press release, the new CEO Emma Walmsley was vague about dividends after 2018.At the same time, GlaxoSmithKline seems to be interested in the consumer healthcare division of Pfizer.It is very likely that GSK will cut its dividend in 2019.A dividend cut will both be necessary if the company wants to do acquisitions and healthy for the business.Which possible scenarios are there with regard to acquisition and dividend options for the future?Glaxosmithkline (LON:GSK) May Have Just Reached An Inflection Point; Investec Securities Downgrades SharesNovember 7, 2017 - By Vivian CurrieGlaxosmithkline (LON:GSK) Receives a DowngradeInvestec Securities has decreased their stock rating for shares of Glaxosmithkline (LON:GSK) to a Hold in a research note revealed to clients on 6 November, and has just set a 12 month PT at GBX 1390.00. This target is 2.17 % from GSK's current share price.

[wormhasturned] 11/11/2017 03:14

May well do, but we’ll soon be knocking on the door of a six year low, and all the dividends of that time will have been for nought. This co. appears to be generating improved returns judging by 3Q., sure the uncertainty of div. cut now being priced in , and the Novartis PUT, and the potential for a major acquisition, but this company is likely to become increasingly vulnerable at these prices. Off course it is a major constituent of tracker funds and numerous other holdings, so if the indices take a puke it will be dragged down too, but we have seen a near 25% fall since June, that should reflect the uncertainty!

[tim 3] 10/11/2017 22:33

Gut feeling is this is going lower, strange as I bought higher!

[bili1946] 10/11/2017 20:51

S G retains a sell; target £10.75........hope they have got this wrong?

[philanderer] 10/11/2017 17:32

Ms Walmsley picking up 20 shares today :-)

[hernando2] 10/11/2017 16:56

The boss woman said they would look at the acquisition and wouldn't say anything about the Divi past 2018.

Income funds are spooked, they would rather lighten their positions whilst the divi is being paid , rather than wait and see what happens.

Income investors like phrases , such as , 'we will have progressive divided policy', 'we will return x throughout the business cycle' ' We are focused on sound capital allocation to ensure a return to our shareholders'

She is signalling a potential move away from a company that sees the Dividend as sacrosanct, in the eyes of these key funds.

IMO

[dr biotech] 10/11/2017 16:52

Think most analysts droppped their price targets because the share price has dropped...

[mj19] 10/11/2017 15:58

Maybe the big boys just want to make this cheap for them

[mj19] 10/11/2017 15:57

Need the share price to come back or the divi just pays for some of this loss

[jadeticl3] 10/11/2017 15:52

I can see no business reason for a fall like this, although I am not disagreeing with the above comments about Emma.
It stands to reason that if so many Analysts are dropping their targets they are also advising their clients that lower prices should be expected, and then these trusting clients feel they should sell.
But this is mostly emotion, not much fact.
We should also recognise that a fair amount of good news about actual products has been released recently. This should eventually overcome solely emotional reactions.

[mj19] 10/11/2017 15:29

If GSK wanted to increase its consumer presence they should buy out the Novartis stake... that would be cheaper that looking at Pfizer!!!Have a good weekend all I don't know when this fall will stop...bloody annoying

[mj19] 10/11/2017 15:25

Trader Michael you said the share price wouldn't t get cheaper.. really

[mj19] 10/11/2017 15:24

I guess we shouldnt be in a rush to buy, this market (casino) gives you lots of chances to buy. When I saw £17 I didn't think I would see £13 again.... I even saw £10 .... and back up to £17+ Just like a cycle ... but we have never had anyone bid for GSK and I guess that would be niceAstra was £25-28 for years and then got a bid since then it's been around £50

[atlantic57] 10/11/2017 15:19

Thanks for the help